DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence

Prostate

Volumn 75, Issue 15, 2015, Pages 1790-1801

  Horning, Aaron M ^a   Awe, Julius A ^b,c,d   Wang, Chiou Miin ^a   Liu, Joseph ^a   Lai, Zhao ^a   Wang, Vickie Yao ^a   Jadhav, Rohit R ^a   Louie, Anna D ^a   Lin, Chun Lin ^a   Kroczak, Tad ^e   Chen, Yidong ^a   Jin, Victor X ^a   Abboud Werner, Sherry L ^a   Leach, Robin J ^a   Hernandez, Javior ^a   Thompson, Ian M ^a   Saranchuk, Jeff ^e   Drachenberg, Darrel ^e   Chen, Chun Liang ^a   Mai, Sabine ^b   Huang, Tim Hui Ming ^a   more..

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF SKÖVDE   (Sweden)

^e UNIVERSITY OF MANITOBA   (Canada)

Author keywords

biochemical recurrence; DNA methylation; plasma; prostate cancer

Indexed keywords

CELL FREE DNA; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); DNA; STEROID 5ALPHA REDUCTASE 2; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; SRD5A2 PROTEIN, HUMAN; STEROID 5ALPHA REDUCTASE; TUMOR MARKER;

ABP RELATED GENE; ADULT; AGED; ANDROGEN SYNTHESIS; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CONTROLLED STUDY; CPG ISLAND; CYP11A1 GENE; DNA DETERMINATION; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE LOCUS; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYL BINDING DOMAIN CAPTURE SEQUENCING; ONCOGENE; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PYROSEQUENCING; RISK ASSESSMENT; SEQUENCE ANALYSIS; SRD5A2 GENE; VALIDATION PROCESS; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTOR; TUMOR RECURRENCE;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; AGED; BIOMARKERS, TUMOR; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84942830759     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23052     Document Type: Article

References (43)

1. Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, Muzio N, Karakiewicz P, Montorsi F, Karnes R, Briganti A,. Survival following biochemical recurrence after radical prostatectomy and Adjuvant Radiotherapy in Patients With Prostate Cancer: The Impact of Competing Causes of Mortality and Patient Stratification. Eur Urol 2013; 64: 557-564.
2. Diaz M, Patterson SG,. Management of androgen-independent prostate cancer. Cancer Control 2004; 11 (6): 364-373.
3. Bickers B, Aukim-Hastie C,. New molecular biomarkers for the prognosis and management of prostate cancer-The post PSA era. Anticancer Res 2009; 29 (8): 3289-3298.
4. Klotz L,. Active surveillance for prostate cancer: Overview and update. Curr Treat Options Oncol 2013; 14 (1): 97-108.
5. Glinsky G, Glinskii A, Stephenson A, Hoffman R, Gerald W,. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113 (6): 913-923.
6. Erho N, Crisan A, Vergara I, Mitra A, Ghadessi M, Buerki C, Bergstralh E, Kollmeyer T, Fink S,. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE 2013; 8 (6): e66855.
7. Rizzardi A, Rosener N, Koopmeiners J, Vogel R, Metzger G, Forster C, Marston L, Tiffany J, McCarthy J, Turley E, Warlick C, Henriksen J, Schmechel S,. Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer 2014; 14 (1): 244.
8. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S,. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 2013; 5 (169):169ra 10.
9. Feinberg A, Tycko B,. The history of cancer epigenetics. Nat Rev Cancer 2004; 4 (2): 143-153.
10. Baylin S, Esteller M, Rountree M, Bachman M, Schuebel K, Herman J,. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001; 10 (7): 687-692.
11. Lienert F, Wirbelauer C, Som I, Dean A, Mohn F, Schübeler D,. Identification of genetic elements that autonomously determine DNA methylation states. Nat Genet 2011; 43 (11): 1091-1097.
12. Strand S, Orntoft T, Sorensen K,. Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci 2014; 15 (9): 16544-16576.
13. Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, Haefliger C, Lesche R, Hartmann A, Corman J, Wheeler T,. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009; 181 (4): 1678-1685.
14. Liu L, Kron K, Pethe V, Demetrashvili N, Nesbitt ME, Trachtenberg J, Ozcelik H, Fleshner NE, Briollais L, Kwast TH, Bapat B,. Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 2011; 129 (10): 2454-2462.
15. Chang K-HH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N,. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA 2011; 108 (33): 13728-13733.
16. Mitsiades N, Sung C, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HI,. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 2012; 72 (23): 6142-6152.
17. Jernberg E, Thysell E, Bovinder Ylitalo E, Rudolfsson S, Crnalic S, Widmark A, Bergh A, Wikstro P,. Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoS ONE 2013; 8 (11):e77407.
18. Jadhav R, Ye Z, Huang R-L, Liu J, Hsu PY, Huang YW, Rangel LB, Lai H-C, Roa JC, Kirma NB, Huang TH-M, Jin VX,. Genome-wide DNA methylation analysis reveals estrogen-mediated epigenetic repression of metallothionein-1 gene cluster in breast cancer. Clin Epigenet 2015; 7 (1): 13.
19. Montgomery R, Mostaghel E, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS,. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008; 68 (11): 4447-4454.
20. Delgado P, Alves B, Gehrke F, Kuniyoshi RK, Wroclavski ML, Giglio A, Fonseca FL,. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol. 2013; 34 (2): 983-986.
21. Swaminathan R, Butt A,. Circulating nucleic acids in plasma and serum. Ann NY Acad Sci 2006; 1075 (1): 1-9.
22. Sueoka-Aragane N, Sato A, Kobayashi N, Ide M, Yokoo M, Nagano Y, Sueoka E, Okada S, Kimura S,. Correlation between plasma DNA and tumor status in an animal model. PLoS ONE 2014; 9 (12): e111881.
23. Siravegna G, Bardelli A,. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol 2014; 15 (8): 449.
24. Murtaza M, Dawson S-J, Tsui D, Gale D, Forshew T, Piskorz A, Parkinson C, Chin S-F, Kingsbury Z, Wong A, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton J, Caldas C, Rosenfeld N,. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497 (7447): 108-112.
25. Luu-The V, Bélanger A, Labrie F,. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrin Metab 2008; 22 (2): 207-221.
26. Liu J-B, Dai C-M, Su X-Y, Cao L, Qin R, Kong Q-B,. Gene microarray assessment of multiple genes and signal pathways involved in androgen-dependent prostate cancer becoming androgen independent. Asian Pac J Cancer Prev 2014; 15 (22): 9791-9795.
27. Payne A, Hales D,. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004; 25 (6): 947-970.
28. Wu Y, Godoy A, Azzouni F, Wilton J, Ip C, Mohler J,. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors. Prostate 2013; 73 (13): 1470-1482.
29. Sewer M, Waterman M,. ACTH modulation of transcription factors responsible for steroid hydroxylase gene expression in the adrenal cortex. Microsc Res Techniq 2003; 61 (3): 300-307.
30. Lewis S, Hedman C, Ziegler T, Ricke W, Jorgensen J,. Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation. Endocrinology 2014; 155 (2): 358-369.
31. Hsieh J, Chen S, Yu H, Chang H,. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: Implications for chemoprevention of prostate cancer. Prostate 2011; 71 (10): 1115-1121.
32. Bauman T, Sehgal P, Johnson K, Pier T, Bruskewitz R, Ricke W, Huang W,. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues. Prostate 2014; 74 (9): 923-932.
33. Hoque A, Yao S, Till C, Kristal A, Goodman P, Hsing A, Tangen C, Platz E, Stanczyk F, Reichardt J, vanBokhoven A, Neuhouser M, Santella R, Figg W, Price D, Parnes H, Lippman S, Ambrosone C, Thompson I,. Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. Urology 2015; 85 (3): 616-620.
34. Kron K, Liu L, Pethe V, Demetrashvili N, Nesbitt M, Trachtenberg J, Ozcelik H, Fleshner N, Briollais L, Kwast T, Bapat B,. DNA methylation of HOXD3 as a marker of prostate cancer progression. Lab Invest 2010; 90 (7): 1060-1067.
35. Thompson I, Ankerst D, Chi C, Lucia M, Goodman P, Crowley J, Parnes H, Coltman C,. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294 (1): 66-70.
36. Bañez L, Sun L, Leenders G, Wheeler T, Bangma C, Freedland S, Ittmann M, Lark A, Madden J, Hartman A, Weiss G, Castaños-Vélez E,. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol 2010; 184 (1): 149-156.
37. Olkhov-Mitsel E, Kwast T, Kron K, Ozcelik H, Briollais L, Massey C, Recker F, Kwiatkowski M, Fleshner N, Diamandis E, Zlotta A, Bapat B,. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics 2012; 7 (9): 1037-1045.
38. Mahapatra S, Klee E, Young C, Sun Z, Jimenez R, Klee G, Tindall D, Donkena KV,. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 2012; 18 (10): 2882-2895.
39. Timp W, Feinberg A,. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013; 13 (7): 497-510.
40. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P,. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 2001; 313 (1-2): 139-142.
41. Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M, Hartmann A, Stamey T, Haefliger C, Weiss G,. Discovery and Validation of 3 Novel DNA Methylation Markers of Prostate Cancer Prognosis. J Urol 2007; 177 (5): 1753-1758.
42. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold L, Trock B, Eisenberger M, Partin A, Nelson W,. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005; 11 (11): 4037-4043.
43. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong S-M, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SKN, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih LM, Oba-Shinjo SM, S Siena, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang T-L, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA. Jr., Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6(224):224ra24.